# Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

> **NCT06669611** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 242 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **DRUG:** Camrelizumab combined GP chemotherapy
- **DRUG:** Camrelizumab combined TPC chemotherapy

## Key facts

- **NCT ID:** NCT06669611
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-27
- **Primary completion:** 2027-11-20
- **Final completion:** 2029-11-20
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06669611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06669611, "Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06669611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*